Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status
Given the favorable toxicity profile and unique mechanism of action, it is worth exploring nivolumab in the treatment of advanced nonsmall cell lung cancer with poor PS patients, who are otherwise offered only best supportive care. [3],[4] Immunotherapy is a potential modality of anticancer therapy...
Gespeichert in:
| Veröffentlicht in: | Indian journal of cancer 2017-01, Vol.54 (1), p.55 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 55 |
| container_title | Indian journal of cancer |
| container_volume | 54 |
| creator | Chandrakanth, M V Noronha, V Joshi, A Patil, V Mahajan, A Prabhash, K |
| description | Given the favorable toxicity profile and unique mechanism of action, it is worth exploring nivolumab in the treatment of advanced nonsmall cell lung cancer with poor PS patients, who are otherwise offered only best supportive care. [3],[4] Immunotherapy is a potential modality of anticancer therapy in lung cancer and may overcome multiple adverse prognostic factors such as poor PS, smoking history, large disease burden, lack of targetable driver mutations, and heavily pretreated disease. Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. |
| doi_str_mv | 10.4103/ijc.IJC_10_17 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1972137108</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A517410336</galeid><sourcerecordid>A517410336</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-d42bbb5079d24bd5401ff7f7fd887462aae57744994200444d121e419d6d7bcb3</originalsourceid><addsrcrecordid>eNptks1rHCEYxqWkNNu0x16DEOhttuo443gMS5qmhPbSQG7iqLPr4uhEnYT893HSNG1hecGP19_rx-MDwCeM1hSj-ovdq_XV943ASGD2Bqww511FGaNHYIUQ5lWD-O0xeJ_SHiFSE9q9A8eEF6xt6QrEH_Y-uHmUPbQ-ZetcgrswmTKD8nnkTEow2TzLbIN_zut76ZXR0AefRukcVKY0bvZbqJaVCB9s3sEphAgnE4cQxyUNU5Z5Th_A20G6ZD6-9Cfg5uvFr8236vrn5dXm_LpSlNBcaUr6vm8Q45rQXjcU4WFgJXTXMdoSKU1Tnkk5pwQhSqnGBBuKuW4161Vfn4Cz3_tOMdzNJmWxD3P05UiBOSO4Zhh1f6mtdEZYP4QcpRptUuK8wWzRuG4LVR2gtsabKF3wZrAl_R-_PsCX0Ga06mDB538Kdka6vEvlYxbN08GbqBhSimYQU7SjjI-LAxZGFEeIV0cU_vRFhbkfjX6l_1igfgLzjrC5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1972137108</pqid></control><display><type>article</type><title>Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status</title><source>MEDLINE</source><source>Medknow Open Access Medical Journals</source><source>Bioline International</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Chandrakanth, M V ; Noronha, V ; Joshi, A ; Patil, V ; Mahajan, A ; Prabhash, K</creator><creatorcontrib>Chandrakanth, M V ; Noronha, V ; Joshi, A ; Patil, V ; Mahajan, A ; Prabhash, K</creatorcontrib><description>Given the favorable toxicity profile and unique mechanism of action, it is worth exploring nivolumab in the treatment of advanced nonsmall cell lung cancer with poor PS patients, who are otherwise offered only best supportive care. [3],[4] Immunotherapy is a potential modality of anticancer therapy in lung cancer and may overcome multiple adverse prognostic factors such as poor PS, smoking history, large disease burden, lack of targetable driver mutations, and heavily pretreated disease. Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer.</description><identifier>ISSN: 0019-509X</identifier><identifier>EISSN: 1998-4774</identifier><identifier>DOI: 10.4103/ijc.IJC_10_17</identifier><identifier>PMID: 29199664</identifier><language>eng</language><publisher>India: Medknow Publications and Media Pvt. Ltd</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - immunology ; Carcinoma, Non-Small-Cell Lung - therapy ; Care and treatment ; Chemotherapy ; Diagnosis ; Disease Progression ; Drug therapy ; Drug-Related Side Effects and Adverse Reactions ; Exanthema - etiology ; Humans ; Immunotherapy - methods ; Lung - diagnostic imaging ; Lung - drug effects ; Lung - pathology ; Lung cancer ; Lung Neoplasms - immunology ; Lung Neoplasms - therapy ; Male ; Medical prognosis ; Metastasis ; Middle Aged ; Monoclonal antibodies ; Mutation ; Neoplasm Staging ; Nivolumab ; Non-small cell lung cancer ; Oncology ; Patient outcomes ; Patients ; Programmed Cell Death 1 Receptor - immunology ; Remission Induction ; Targeted cancer therapy ; Vertebrae</subject><ispartof>Indian journal of cancer, 2017-01, Vol.54 (1), p.55</ispartof><rights>COPYRIGHT 2017 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications & Media Pvt. Ltd. Jan/Mar 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-d42bbb5079d24bd5401ff7f7fd887462aae57744994200444d121e419d6d7bcb3</citedby><cites>FETCH-LOGICAL-c424t-d42bbb5079d24bd5401ff7f7fd887462aae57744994200444d121e419d6d7bcb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29199664$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chandrakanth, M V</creatorcontrib><creatorcontrib>Noronha, V</creatorcontrib><creatorcontrib>Joshi, A</creatorcontrib><creatorcontrib>Patil, V</creatorcontrib><creatorcontrib>Mahajan, A</creatorcontrib><creatorcontrib>Prabhash, K</creatorcontrib><title>Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status</title><title>Indian journal of cancer</title><addtitle>Indian J Cancer</addtitle><description>Given the favorable toxicity profile and unique mechanism of action, it is worth exploring nivolumab in the treatment of advanced nonsmall cell lung cancer with poor PS patients, who are otherwise offered only best supportive care. [3],[4] Immunotherapy is a potential modality of anticancer therapy in lung cancer and may overcome multiple adverse prognostic factors such as poor PS, smoking history, large disease burden, lack of targetable driver mutations, and heavily pretreated disease. Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer.</description><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - immunology</subject><subject>Carcinoma, Non-Small-Cell Lung - therapy</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Diagnosis</subject><subject>Disease Progression</subject><subject>Drug therapy</subject><subject>Drug-Related Side Effects and Adverse Reactions</subject><subject>Exanthema - etiology</subject><subject>Humans</subject><subject>Immunotherapy - methods</subject><subject>Lung - diagnostic imaging</subject><subject>Lung - drug effects</subject><subject>Lung - pathology</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - immunology</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Mutation</subject><subject>Neoplasm Staging</subject><subject>Nivolumab</subject><subject>Non-small cell lung cancer</subject><subject>Oncology</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Programmed Cell Death 1 Receptor - immunology</subject><subject>Remission Induction</subject><subject>Targeted cancer therapy</subject><subject>Vertebrae</subject><issn>0019-509X</issn><issn>1998-4774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptks1rHCEYxqWkNNu0x16DEOhttuo443gMS5qmhPbSQG7iqLPr4uhEnYT893HSNG1hecGP19_rx-MDwCeM1hSj-ovdq_XV943ASGD2Bqww511FGaNHYIUQ5lWD-O0xeJ_SHiFSE9q9A8eEF6xt6QrEH_Y-uHmUPbQ-ZetcgrswmTKD8nnkTEow2TzLbIN_zut76ZXR0AefRukcVKY0bvZbqJaVCB9s3sEphAgnE4cQxyUNU5Z5Th_A20G6ZD6-9Cfg5uvFr8236vrn5dXm_LpSlNBcaUr6vm8Q45rQXjcU4WFgJXTXMdoSKU1Tnkk5pwQhSqnGBBuKuW4161Vfn4Cz3_tOMdzNJmWxD3P05UiBOSO4Zhh1f6mtdEZYP4QcpRptUuK8wWzRuG4LVR2gtsabKF3wZrAl_R-_PsCX0Ga06mDB538Kdka6vEvlYxbN08GbqBhSimYQU7SjjI-LAxZGFEeIV0cU_vRFhbkfjX6l_1igfgLzjrC5</recordid><startdate>201701</startdate><enddate>201701</enddate><creator>Chandrakanth, M V</creator><creator>Noronha, V</creator><creator>Joshi, A</creator><creator>Patil, V</creator><creator>Mahajan, A</creator><creator>Prabhash, K</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201701</creationdate><title>Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status</title><author>Chandrakanth, M V ; Noronha, V ; Joshi, A ; Patil, V ; Mahajan, A ; Prabhash, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-d42bbb5079d24bd5401ff7f7fd887462aae57744994200444d121e419d6d7bcb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - immunology</topic><topic>Carcinoma, Non-Small-Cell Lung - therapy</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Diagnosis</topic><topic>Disease Progression</topic><topic>Drug therapy</topic><topic>Drug-Related Side Effects and Adverse Reactions</topic><topic>Exanthema - etiology</topic><topic>Humans</topic><topic>Immunotherapy - methods</topic><topic>Lung - diagnostic imaging</topic><topic>Lung - drug effects</topic><topic>Lung - pathology</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - immunology</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Mutation</topic><topic>Neoplasm Staging</topic><topic>Nivolumab</topic><topic>Non-small cell lung cancer</topic><topic>Oncology</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Programmed Cell Death 1 Receptor - immunology</topic><topic>Remission Induction</topic><topic>Targeted cancer therapy</topic><topic>Vertebrae</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chandrakanth, M V</creatorcontrib><creatorcontrib>Noronha, V</creatorcontrib><creatorcontrib>Joshi, A</creatorcontrib><creatorcontrib>Patil, V</creatorcontrib><creatorcontrib>Mahajan, A</creatorcontrib><creatorcontrib>Prabhash, K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Indian journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chandrakanth, M V</au><au>Noronha, V</au><au>Joshi, A</au><au>Patil, V</au><au>Mahajan, A</au><au>Prabhash, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status</atitle><jtitle>Indian journal of cancer</jtitle><addtitle>Indian J Cancer</addtitle><date>2017-01</date><risdate>2017</risdate><volume>54</volume><issue>1</issue><spage>55</spage><pages>55-</pages><issn>0019-509X</issn><eissn>1998-4774</eissn><abstract>Given the favorable toxicity profile and unique mechanism of action, it is worth exploring nivolumab in the treatment of advanced nonsmall cell lung cancer with poor PS patients, who are otherwise offered only best supportive care. [3],[4] Immunotherapy is a potential modality of anticancer therapy in lung cancer and may overcome multiple adverse prognostic factors such as poor PS, smoking history, large disease burden, lack of targetable driver mutations, and heavily pretreated disease. Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer.</abstract><cop>India</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><pmid>29199664</pmid><doi>10.4103/ijc.IJC_10_17</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0019-509X |
| ispartof | Indian journal of cancer, 2017-01, Vol.54 (1), p.55 |
| issn | 0019-509X 1998-4774 |
| language | eng |
| recordid | cdi_proquest_journals_1972137108 |
| source | MEDLINE; Medknow Open Access Medical Journals; Bioline International; EZB-FREE-00999 freely available EZB journals |
| subjects | Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cancer therapies Carcinoma, Non-Small-Cell Lung - immunology Carcinoma, Non-Small-Cell Lung - therapy Care and treatment Chemotherapy Diagnosis Disease Progression Drug therapy Drug-Related Side Effects and Adverse Reactions Exanthema - etiology Humans Immunotherapy - methods Lung - diagnostic imaging Lung - drug effects Lung - pathology Lung cancer Lung Neoplasms - immunology Lung Neoplasms - therapy Male Medical prognosis Metastasis Middle Aged Monoclonal antibodies Mutation Neoplasm Staging Nivolumab Non-small cell lung cancer Oncology Patient outcomes Patients Programmed Cell Death 1 Receptor - immunology Remission Induction Targeted cancer therapy Vertebrae |
| title | Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T17%3A50%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nivolumab%20instills%20hope%20in%20a%20hopeless%20situation%20in%20advanced%20nonsmall%20cell%20lung%20cancer%20with%20poor%20performance%20status&rft.jtitle=Indian%20journal%20of%20cancer&rft.au=Chandrakanth,%20M%20V&rft.date=2017-01&rft.volume=54&rft.issue=1&rft.spage=55&rft.pages=55-&rft.issn=0019-509X&rft.eissn=1998-4774&rft_id=info:doi/10.4103/ijc.IJC_10_17&rft_dat=%3Cgale_proqu%3EA517410336%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1972137108&rft_id=info:pmid/29199664&rft_galeid=A517410336&rfr_iscdi=true |